Discerning the clinical relevance of biomarkers in early stage breast cancer
ConclusionsPatients faced with multi-faceted decisions consider personal experience and perceived risk of recurrent disease. Biomarkers providing information on likelihood of toxicity risk do influence treatment choices, and patients may accept reduced benefit when faced with higher risk of toxicity in the curative setting.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Brain | Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Chemotherapy | Congestive Heart Failure | Heart | Heart Failure | HER2 | Neurology | Peripheral Neuropathy | Toxicology